Sanofi earns FDA approval for type 2 diabetes treatment

The Food and Drug Administration recently approved Sanofi's new type 2 diabetes treatment Soliqua.

Soliqua is a once-daily injection that combines Lantus, or insulin glargine, with lixisenatide. The treatment is intended for adults with type 2 diabetes who cannot control their glycemic levels with basal insulin.

Paris, France-based Sanofi expects Soliqua to hit pharmacy shelves in January 2017.

More articles on supply chain:

6 latest FDA approvals
Bundled payments reach a turning point: Four strategies for success
Gartner names top 25 supply chains in healthcare

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.